Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.
Makaleler > Özet · 2011
Yazarlar: F. ICLI, K. ALTUNDAG, U. COSKUN, S. PAYDAS, G. BASARAN, P. SAIP, G. G. DOGU, Y. ERALP, RÜÇHAN USLU, A. SEVINC, H. ONUR, N. M. MANDEL, C. SEZGIN, Metin ALTINBAŞ, N. GULER, A. ISIKDOGAN, Erhan GÖKMEN, K. UYGUN, Z. USTUNER, A. YAREN
JOURNAL OF CLINICAL ONCOLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2011, cilt 29, ss 629-629